Craig Koniver, M.D., is a physician in Charleston, South Carolina who described his peptide protocols on the Huberman Lab podcast on October 7, 2024. We read that episode’s transcript and his clinic’s own peptide pages, then checked each substance against the FDA record, the product labels and the published trials. Most of what he describes is compounded, and most of it has no completed human trial behind the use he describes. One substance on his list, tesamorelin, is an FDA-approved drug for a narrow condition.
The direct answer: the protocols Craig Koniver describes are prescriber-led compounded treatment rather than approved medicine, and the part of his advice that holds up best is his sourcing standard, not the peptides.
Craig Koniver Peptides: The Short Answer
The episode’s show notes describe him as a board-certified physician trained at Brown University and Thomas Jefferson University, and his clinic’s site states that peptide and hormone therapy there is prescribed and supervised by a licensed physician.
His practice is built on growth hormone secretagogues. Ipamorelin is the peptide his clinic says he reaches for first, with tesamorelin, sermorelin and CJC-1295 in the same family. BPC-157 he calls the most-used peptide of his earlier years, and MOTS-c appears in a fat-loss combination with AOD-9604 and tesamorelin.
Measured against the federal record, that list splits in two. Tesamorelin has an approved product and randomized trials, in one population. The rest are compounded substances with thin or absent human data, and his own website says so about several of them.
What He Says the Evidence Contains
His clinic publishes a peptide page that is more candid than most sales copy in this market. BPC-157 is described there as “researched mostly in animals for tissue repair, gut protection, and inflammation.” FGL, another peptide on the same page, is marked “Research-only: promising animal data, no human trials, so we don’t use it yet.”
That last line shows a standard. The question here is whether the peptides he does use carry the human data the episode implies.
On ipamorelin, his page calls it “the most selective of its family” and says it is his first choice. That selectivity claim comes from animal work and a small pharmacokinetic study in healthy volunteers, which is a different thing from a treatment effect.
BPC-157: Animal Research, an FDA Briefing and a Draft Policy
In the episode he describes BPC-157 as a peptide he used with most patients, starting at a conservative dose drawn from animal studies and later reaching a dose ten times higher, on a five-days-on, two-days-off schedule.
The federal record does not support the treatment claims. FDA placed BPC-157 in Category 2, the tier for bulk substances that may present significant safety risks, in September 2023. It stayed there until April 22, 2026, when the agency moved it to a table of substances nominated but withdrawn, while keeping its safety write-up published.
In July 2026, FDA’s briefing for the Pharmacy Compounding Advisory Committee found insufficient evidence to conclude that BPC-157 is effective for ulcerative colitis, the use the agency evaluated, and raised characterization, safety and immunogenicity concerns. The committee then voted 8 to 6 with one abstention to recommend it, a split tally that is advice to FDA and not a decision. The full sequence is set out in our page on the July 2026 peptide vote.
Since then, the picture has moved again without becoming an approval. On October 28, 2026, HHS released a draft enforcement discretion policy covering six peptides, BPC-157 among them. It says the department does not intend to pursue enforcement against state-licensed pharmacies and physicians compounding those substances under ten listed conditions. The Federal Register notice that followed on October 30, 2026, at 91 FR 68526, calls it a draft and states that it is not binding on HHS or the public. Our page on what the October policy allows walks through the conditions.
A patient hearing BPC-157 praised on a podcast is hearing about a substance with no approved product, which FDA’s reviewers found insufficiently evidenced for the one use they examined, and which now sits inside a draft enforcement position open for comment.
Ipamorelin: One Patient Trial, a Missed Endpoint, a 12 to 0 Vote
Ipamorelin, the peptide his clinic says he reaches for first, has one patient trial and no approval. That trial tested intravenous ipamorelin in 117 patients recovering from bowel surgery, against placebo, and missed its primary endpoint: median time to tolerating a solid meal was 25.3 hours on the drug and 32.6 hours on placebo, with a reported p value of 0.15.
The human pharmacology paper behind the growth hormone claims is a dose escalation study in eight healthy male volunteers per infusion rate, measuring hormone concentrations and nothing else. No study has measured ipamorelin against muscle, fat, sleep or recovery in people.
In August 2024, FDA’s briefing for the compounding committee stated that there are “no data to support the effectiveness” of ipamorelin for the subcutaneous route, which is the route a telehealth patient would use at home. On October 29, 2024, the committee voted 0 yes, 12 no and 1 abstention on the free base, and the same on the acetate. The detail and the citations are in our page on ipamorelin and the 12 to 0 vote.
Tesamorelin: The One With an Approved Product and a Narrow Label
Tesamorelin is the exception, and the label states its limits. EGRIFTA SV is indicated for the reduction of excess abdominal fat in adults with HIV and lipodystrophy. The prescribing information published on DailyMed on July 31, 2026, says the product is “not indicated for weight loss management as it has a weight neutral effect.”
The trials behind it are real. Falutz and colleagues pooled two phase 3 studies of 806 patients in the Journal of Clinical Endocrinology and Metabolism in 2010. At 26 weeks, visceral fat fell by 15.4 percent against placebo, and abdominal subcutaneous fat did not move. The fat that responded is the fat measured on a CT scan, not the fat a tape measure finds. Our page on tesamorelin results carries the trial numbers and the label’s monitoring requirements, including IGF-1 and glucose.
The episode’s clinical picture widens past the label, and the evidence thins there. His clinic describes a fat-loss combination of tesamorelin with AOD-9604 and MOTS-c, and describes patients reporting less belly fat. No trial has tested that combination. AOD-9604 has its own problem, covered in our AOD-9604 page: the human work ran on a different scale and route from what gets sold.
The Claims That Rest on Mechanism, Not on People
Two claims in the episode sound like findings and are not. The first is that BPC-157 upregulates the growth hormone receptor, so combining it with a growth hormone releasing peptide lets a prescriber use less of the second one. That is a mechanistic argument, and no human study has measured the combination against either peptide alone.
The second is sleep. The host describes a personal experiment with pinealon, tracked on his own sleep device, in which rapid eye movement sleep roughly doubled. That is one sleeper’s tracker reading, not a trial result.
Craig Koniver on Sourcing, and Why That Part Holds Up
The strongest material in the episode is about where peptides come from. He describes working with compounding pharmacies he says are inspected and held to sterility and purity standards, and he separates those from research-grade vials sold online.
That concern is not a marketing position. FDA’s Category 2 write-ups for these substances cite immunogenicity from aggregation and peptide-related impurities as reasons for concern. The October 2026 HHS draft makes the same point in its conditions: the bulk substance has to come from an FDA-registered manufacturer, be identified in a valid certificate of analysis, and be tested for purity, potency and contaminants including endotoxins rather than assumed clean.
A patient can check those things. Ask for the lot’s certificate of analysis. Ask which pharmacy made the vial and whether it is registered as a 503A or 503B facility. Ask who holds the prescription and where that prescriber is licensed. A clinic selling a peptide it cannot trace is the risk the episode warns about.
What To Ask Before You Follow Any Protocol From a Podcast
A podcast protocol describes one clinician’s practice with his own patients. The questions that separate a supervised program from a vial in the mail are the same anywhere.
- Which FDA-approved product is this, and if there is none, which pharmacy compounded it and under what authority?
- What outcome are we measuring, and on what date do we decide whether it worked?
- Which labs are checked before and during treatment, and who reads them?
- What is the plan if a side effect appears, and who answers the phone?
- Is the prescriber licensed in your state, and can you verify that license yourself?
Our clinic directory lists clinics by city, and we tell readers to check each clinic’s license and prescribing record before paying anything. The compounds hub explains each peptide, and the page on BPC-157 collects the federal record in one place.
Frequently asked questions
Who is Craig Koniver?
Craig Koniver, M.D., is a physician who practices in Charleston, South Carolina and who described his peptide and hormone protocols on the Huberman Lab podcast on October 7, 2024. The episode’s show notes describe him as board-certified and trained at Brown University and Thomas Jefferson University.
What peptides does Craig Koniver recommend?
In the episode and on his clinic’s peptide page, ipamorelin is the growth hormone peptide he reaches for first, with tesamorelin, sermorelin and CJC-1295 in the same family. BPC-157 is described as his most-used peptide of earlier years, MOTS-c appears in a fat-loss combination with AOD-9604 and tesamorelin, and GHK-Cu is kept as a topical.
Are the protocols in that episode FDA approved?
No. Of the peptides discussed, tesamorelin is the one with an FDA-approved product, EGRIFTA SV, and that approval covers excess abdominal fat in adults with HIV and lipodystrophy. The others are compounded substances with no approved product, and FDA’s advisory committee voted 12 to 0 against adding ipamorelin to the compounding list in October 2024.
Does BPC-157 have human trials behind the claims?
FDA’s July 2026 briefing found insufficient evidence to conclude that BPC-157 is effective for ulcerative colitis and raised characterization, safety and immunogenicity concerns. The compounding committee recommended it on an 8 to 6 vote with one abstention, which is advice to the agency rather than a decision. No approved product contains it.
Has a combined peptide stack been tested in a trial?
No. The combination of BPC-157 with a growth hormone releasing peptide rests on a proposed mechanism that no human study has measured. The tesamorelin, AOD-9604 and MOTS-c combination his clinic describes has no trial behind it either.
Should I follow a peptide protocol I heard on a podcast?
A protocol described on a podcast reflects one clinician’s practice with his own patients and his own monitoring. Before treatment, confirm which product and pharmacy are involved, what outcome will be measured, which labs are monitored, and whether the prescriber is licensed in your state. Doses vary by prescriber and pharmacy, and the decision belongs to a licensed clinician who knows your history.
Sources
- Huberman Lab, “Dr. Craig Koniver: Peptide & Hormone Therapies for Health, Performance & Longevity,” episode page and transcript, published October 7, 2024. hubermanlab.com episode page
- Koniver Wellness, “Peptide Research in Charleston, SC,” clinic page describing its own peptide list, retrieved November 7, 2026. Cited as plain text at koniverwellness.com/peptide-research because it is a clinic’s marketing page.
- Koniver Wellness, “About Dr. Craig Koniver,” clinic page, retrieved November 7, 2026. Cited as plain text at koniverwellness.com/about.
- Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 1998. PubMed 9849822
- Gobburu JVS, Agersø H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin in human volunteers. Pharmaceutical Research, 1999. PubMed 10496658
- Beck DE, Sweeney WB, McCarter MD. Prospective, randomized, controlled study of ipamorelin for postoperative ileus in bowel resection patients. International Journal of Colorectal Disease, December 2014. PubMed 25331030
- FDA, Briefing Document for the Pharmacy Compounding Advisory Committee meeting of October 29, 2024, dated August 19, 2024, on ipamorelin. fda.gov briefing document
- FDA, Final Summary Minutes of the Pharmacy Compounding Advisory Committee meeting of October 29, 2024, approved January 15, 2025. fda.gov meeting minutes
- FDA, Briefing Document for the Pharmacy Compounding Advisory Committee meeting of July 23 and 24, 2026, including BPC-157. fda.gov briefing document
- FDA, Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, page dated April 22, 2026, retrieved November 7, 2026. fda.gov safety page
- HHS, draft enforcement discretion policy on compounding with six peptide bulk drug substances, released October 28, 2026, and Federal Register notice of availability, 91 FR 68526, October 30, 2026.
- EGRIFTA SV (tesamorelin) prescribing information, Theratechnologies, DailyMed, published July 31, 2026. DailyMed label
- Falutz J, Mamputu JC, Potvin D, Moyle G, et al. Effects of tesamorelin in HIV-infected patients with excess abdominal fat: pooled analysis of two phase 3 trials. Journal of Clinical Endocrinology and Metabolism, 2010. PubMed 20554713
This article is for information. It is not medical advice, and it is not a recommendation to use or avoid any product. Compounded peptides are not FDA-approved, and FDA does not review their safety, effectiveness or quality before they are marketed. Doses vary by prescriber and pharmacy, and anyone considering treatment should consult a licensed clinician who can review their own history and monitor them.